BioTuesdays

USPTO grants Allerity patent covering stenoparib dosing regimen, extending protection into 2045

Allarity Logo

Allarity Therapeutics (NASDAQ: ALLR) has announced that the United States Patent and Trademark Office (USPTO) has granted a patent covering stenoparib treatment regimens, with protection for the claimed methods extending into 2045.

According to Allarity, the 36 allowed claims cover twice-daily oral administration of stenoparib, including specified dose levels and treatment schedules relevant to Allarity’s clinical development program. They also encompass methods of treating advanced ovarian cancer and other solid tumors, including breast, colon, pancreatic and prostate cancers, as well as patients whose disease has not responded to prior therapies, including other PARP inhibitors.

In a statement, Thomas Jensen, CEO of Allarity, commented, “The commercial significance of this patent is enormous. Its coverage of our twice-daily dosing strategy is critical as this is the dosing regimen we intend to advance to pivotal trials. A protection period extending into 2045 strengthens the foundation for continued investment in stenoparib and fuels future partnering discussions as we generate the clinical data needed to support FDA approval.”

The patent, titled Methods for Treating Cancer, complements Allarity’s previously issued U.S. patent covering its stenoparib-specific Drug Response Predictor companion diagnostic. The company stated that, together, the patent supports its strategy to develop stenoparib alongside a proprietary approach to identifying patients most likely to benefit.

POWERED BY

Stay Ahead in Healthcare & Life Sciences